文献速递皮肤肿瘤

TVEC联合免疫检查点抑制剂增加皮肤免疫相关不良事件风险

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
PubMed 文献 · J Am Acad Dermatol · 2023-03-21

本研究在麻省总医院布莱根医疗系统纳入接受免疫检查点抑制剂(ICI)单用或联合talimogene laherparepvec(TVEC)的皮肤恶性肿瘤患者,分析皮肤免疫相关不良事件(cirAE)发生情况。结果显示,ICI单用组cirAE发生率为32.3%,ICI联合TVEC组为38.7%;校正协变量后,联合TVEC与cirAE风险增加约2倍相关(HR 2.03,P=.006)。

要点

  • ICI单用组cirAE发生率为32.3%,ICI联合TVEC组为38.7%。
  • 校正后联合TVEC与cirAE风险增加约2倍相关(HR 2.03,P=.006)。
  • 作者认为该发现为皮肤科和肿瘤科医生咨询和监测患者提供潜在机会。

核心结论

  • 与单用ICI相比,ICI联合TVEC与cirAE发生风险增加约2倍相关(HR 2.03,P=.006)。
  • 作者认为这些发现为皮肤科医生和肿瘤科医生在咨询和监测患者方面提供了潜在机会。

研究设计与样本

  • 在麻省总医院布莱根医疗系统开展的回顾性队列研究,纳入接受ICI联合或不联合TVEC治疗的皮肤恶性肿瘤患者。
  • 采用Pearson χ2检验或Fisher精确检验分析分类变量,t检验或Kruskal-Wallis检验分析连续变量;为校正不朽时间偏倚,采用校正的时变Cox比例风险模型。

主要发现

  • ICI单用组cirAE发生率为32.3%,ICI联合TVEC组为38.7%。
  • 校正协变量后,ICI联合TVEC组cirAE发生风险为ICI单用组的2.03倍(HR 2.03,P=.006)。

关键数值与推荐

  • ICI单用组cirAE发生率32.3%,ICI联合TVEC组38.7%。
  • 校正后HR 2.03(P=.006),比较对象为ICI联合TVEC组 vs ICI单用组。

临床怎么用

  • 作者认为这些发现为皮肤科医生和肿瘤科医生在咨询和监测患者方面提供了潜在机会。

局限性

  • 回顾性研究。
  • 来自三级学术中心的样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies have shown that combining immune checkpoint inhibitors (ICIs) with talimogene laherparepvec (TVEC) may improve antitumor responses. However, the risk of developing cutaneous immune-related adverse events (cirAEs) in patients treated with ICI and TVEC has not been studied. OBJECTIVE: To evaluate the differences in cirAE development between patients treated with ICI alone and both ICI and TVEC (ICI + TVEC). METHODS: Patients with cutaneous malignancy receiving ICI with or without TVEC therapy at the Massachusetts General Brigham healthcare system were included. CirAE development, time from ICI initiation to cirAE, cirAE grade, cirAE morphology, and survival were analyzed. Pearson's χ2 test or Fisher's exact test for categorical variables and t test or Kruskal-Wallis test for continuous variables were used. To account for immortal time bias, we performed adjusted time-varying Cox proportional hazards modeling. RESULTS: The rate of cirAE development was 32.3% and 38.7% for ICI only and ICI + TVEC, respectively. After adjusting for covariates, ICI + TVEC was associated with a 2-fold increased risk of cirAE development (hazard ratio: 2.03, P = .006) compared to patients receiving ICI therapy alone. LIMITATIONS: The retrospective nature and limited sample size from a tertiary-level academic center. CONCLUSION: These findings underscore potential opportunities for dermatologists and oncologists in counseling and monitoring patients.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Leung BW, Wan G, Nguyen N, et al. Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study. J Am Acad Dermatol. 2023. PMID: 36944564. doi:10.1016/j.jaad.2023.02.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。